Ameriprise
JANX icon

Ameriprise’s Janux Therapeutics JANX Stock Holding History

Ameriprise’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-256,055
Closed -$6.26M – 4151
2025
Q3 		$6.26M Buy
256,055
+470
+0.2% +$11.4K ﹤0.01% 2262
2025
Q2 		$5.9M Sell
255,585
-5,677
-2% -$150K ﹤0.01% 2237
2025
Q1 		$7.05M Buy
261,262
+246,356
+1,653% +$9.29M ﹤0.01% 2041
2024
Q4 		$798K Buy
14,906
+9,636
+183% +$510K ﹤0.01% 3335
2024
Q3 		$239K Buy
+5,270
New +$229K ﹤0.01% 3707

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ameriprise's JANX Position: Q4 2025 in Review

Ameriprise sold out of Janux Therapeutics (JANX) in Q4 2025, closing a stake of 256,055 shares — an estimated $6.26M sold.

Ameriprise first reported a position in JANX in Q3 2024 and held it in 5 quarters. The position peaked at $7.05M in Q1 2025. 176 funds tracked by Wall St. Rank hold JANX as of Q4 2025.

  • Ameriprise reported no remaining Janux Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Ameriprise sold 256,055 Janux Therapeutics shares in Q4 2025, an estimated $6.26M.
  • Ameriprise first reported a position in Janux Therapeutics in Q3 2024 and held it in 5 quarters.
  • Ameriprise's Janux Therapeutics position peaked at $7.05M in Q1 2025.
  • 176 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2025.

Based on Ameriprise's 13F filing for Q4 2025, filed 17 Feb 2026.